SIGRID THERAPEUTICS
LIVE

Serial Number

98365730

Owner

Sigrid Therapeutics AB

Attorney

Bradley L. Cohn

Filing Date

Jan 19, 2024

Add to watchlist:

No watchlists yet
View on USPTO

SIGRID THERAPEUTICS Trademark

Serial Number: 98365730

SIGRID THERAPEUTICS is a trademark filed by Sigrid Therapeutics AB on January 19, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus). The application is currently pending registration.

Owner Contact Info

Sigrid Therapeutics AB (5 trademarks)

Birger Jarlsgatan 57

Entity Type: 98

Trademark Details

Filing Date

January 19, 2024

Registration Date

Not Registered

Published for Opposition

December 3, 2024

Goods & Services

Nutritional supplements; dietary supplements; dietary and nutritional supplements for the treatment and prevention of obesity and being overweight; dietary and nutritional supplements for boosting daily energy levels, balancing blood sugar, and maintaining healthy weight; dietary and nutritional supplements for the treatment and regulation of obesity, body weight, body fat, body composition, body weight circumference, cholesterol, LDL cholesterol levels and blood lipids; dietetic foods adapted for medical purposes; dietetic foods and beverages adapted for medical use; dietetic foods for the prevention and treatment of prediabetes, diabetes, glycemic control and for the improvement of overall metabolic health; dietetic foods for the treatment and prevention of obesity and being overweight; dietetic foods for the treatment and regulation of obesity, body weight, body fat, body composition, body weight circumference, cholesterol, LDL cholesterol levels and blood lipids; dietetic preparations adapted for medical use; dietetic substances in the nature of tablets, capsules, liquid formulations, drinks, shots, shakes, gels, powders and suspensions adapted for medical use; dietetic preparations and substances for glycemic control; dietetic preparations and substances for the prevention and treatment of prediabetes, diabetes and for the improvement of overall metabolic health; dietary and nutritional supplements for glycemic control; health food supplements for persons with special dietary requirements; pharmaceuticals and natural remedy preparations for the treatment and prevention of obesity, being overweight, prediabetes, diabetes, glycemic control and for the improvement of overall metabolic health; preparations for use in naturopathy for the treatment and prevention of obesity, being overweight, prediabetes, diabetes, glycemic control and for the improvement of overall metabolic health; chemical preparations for medical purposes for the treatment and prevention of obesity, being overweight, prediabetes, diabetes, glycemic control and for the improvement of overall metabolic health; pharmaceutical preparations and chemico- pharmaceutical preparations for the treatment and prevention of obesity, being overweight, prediabetes, diabetes, glycemic control and for the improvement of overall metabolic health; chemical preparations for pharmaceutical purposes for the treatment and prevention of obesity, being overweight, prediabetes, diabetes, glycemic control and for the improvement of overall metabolic health; pharmaceutical preparations and substances for glycemic control; pharmaceutical preparations and substances for the prevention and treatment of prediabetes, diabetes and for the improvement of overall metabolic health; pharmaceutical preparations in the form of tablets, capsules, liquid formulations, drinks, shots, shakes, gels, powders and suspensions for use in glycemic control; pharmaceutical preparations in the form of tablets, capsules, liquid formulations, drinks, shots, shakes, gels, powders and suspensions for use in the prevention and treatment of prediabetes, diabetes and for the improvement of overall metabolic health; pharmaceutical preparations and substances and dietary and nutritional substances in the form of tablets, capsules, liquid formulations, drinks, shots, shakes, gels, powders and suspensions, all for use in the treatment and regulation of obesity, body weight, body fat, body composition, body weight circumference, cholesterol and LDL cholesterol levels, liver disease, steatohepatitis, infantile colic, gut microbiota, insulin levels and resistance, blood lipids, diarrhea, constipation, colitis; pharmaceutical preparations and substances and dietary and nutritional substances in the form of tablets, capsules, liquid formulations, drinks, shots, shakes, gels, powders and suspensions, all for use in the treatment and regulation of intestinal injury or inflammation, Crohn's disease, cardiovascular risk factors, post bariatric surgery patients, and not including products primarily for use in the treatment of angina pectoris and high blood pressure

Surgical and medical devices for the treatment and prevention of obesity, being overweight, prediabetes, diabetes, glycemic control and for the improvement of overall metabolic health; capsulated medical devices for the treatment and prevention of obesity, being overweight, prediabetes, diabetes, glycemic control and for the improvement of overall metabolic health; medical devices for the treatment and prevention of obesity and being overweight, and for use in weight control; medical devices for the treatment and prevention of prediabetes, diabetes and glycemic control, and for the improvement of overall metabolic health; medical devices for use in the prevention and treatment of prediabetes and diabetes; orally administered medical devices for the treatment and prevention of obesity, being overweight, prediabetes, diabetes, glycemic control and for the improvement of overall metabolic health; surgical and medical devices, capsulated devices and orally administered medical devices all for use in the treatment and regulation of obesity, body weight, body fat, body composition, body weight circumference, cholesterol and LDL cholesterol levels, liver disease, steatohepatitis, infantile colic, gut microbiota, insulin levels and resistance, blood lipids, diarrhea, constipation, intestinal injury or inflammation, colitis, Crohn's disease, cardiovascular risk factors, post bariatric surgery patients

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 14, 2026 EXRA
SOU EXTENSION 2 GRANTED
Jan 14, 2026 EX2G
SOU EXTENSION 2 FILED
Jan 13, 2026 EXT2
SOU TEAS EXTENSION RECEIVED
Jan 13, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 2, 2025 EXRA
SOU EXTENSION 1 GRANTED
Jul 1, 2025 EX1G
SOU EXTENSION 1 FILED
Jul 1, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
Jul 1, 2025 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jan 14, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 3, 2024 NPUB
PUBLISHED FOR OPPOSITION
Dec 3, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 27, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 9, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 8, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 8, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 8, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 21, 2024 GNRN
NON-FINAL ACTION E-MAILED
Aug 21, 2024 GNRT
NON-FINAL ACTION WRITTEN
Aug 21, 2024 CNRT
ASSIGNED TO EXAMINER
Aug 15, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 18, 2024 NWOS
NEW APPLICATION ENTERED
Jan 19, 2024 NWAP